Supported by preclinical data showing a correlation of extent of MAPK inhibition with response to BRAFi treatment (44) and data emerging from trials evaluating MEK inhibitors (Selumetinib, Trametinib and Binimetinib) in pediatric glioma patients (45–49), subsequent studies assessed the effect of combinatorial BRAFV600E and MEK inhibition. Here, MAP2K7 is linked to glioma.